Berlin, September 24, 2015 – The biotechnology company MOLOGEN AG will present a poster on the immunotherapy MGN1703 at the European Cancer Congress (ECC 2015) in Vienna (September 25 – 29, 2015). The poster is featuring data from the phase II IMPACT trial in colorectal cancer patients. Furthermore, in the framework of the conference, an investigator meeting is scheduled for the randomized lung cancer study IMPULSE.
Abstract details:
Abstract number: 2089 (used in the programme and online abstract book)
Title: “Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study”
Poster presentation: “Gastrointestinal Malignancies – Colorectal Cancer” on September 27, 2015 from 9:15 a.m. to 11:15 a.m. in Hall C.
For more information on the ECC 2015 please visit the website www.europeancancercongress.org .
MOLOGEN AG
With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.
The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV.
MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need.
MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200).
www.mologen.com
Help employers find you! Check out all the jobs and post your resume.
